Summary of Artivion Q2 2026 Earnings Call

1Key Financial Results and Metrics

Total Revenues: $125.8 million, up 9% year-over-year.

Adjusted EBITDA: $26.4 million, a 7% increase from $24.8 million in Q2 2025. Adjusted EBITDA margin decreased to 21%.

Product Performance:

Stent Grafts: Revenue grew 12%.

On-X Valves: Revenue increased 18%.

Tissue Processing: Revenue up 1%.

BioGlue: Revenue declined 2%.

Free Cash Flow: Negative $12 million, impacted by integration costs related to the Endospan acquisition and a $10.2 million payment for transaction bonuses.

Net Leverage Ratio: 3.1, reflecting recent borrowings for the Endospan acquisition.

2Strategic Updates and Business Highlights

FDA Approvals: Received PMA approval for the AMDS hybrid prosthesis, expected to enhance sales and account conversions. The NEXUS Aortic Arch Stent Graft System was also acquired, completing Artivion's aortic arch portfolio.

Sales Strategy: Focus on building inventory and augmenting the U.S. sales team for NEXUS, with a full launch planned for January 2027.

Market Positioning: Artivion is positioned as a leader in the aortic arch market with a comprehensive portfolio, including AMDS, NEXUS, and Arcevo.

Clinical Data: Positive long-term outcomes for the SynerGraft pulmonary valve were published, reinforcing its market position.

3Forward Guidance and Outlook

Revenue Growth: Expecting adjusted constant currency growth of 7% to 11% for the full year 2026, translating to reported revenues of $480 million to $496 million.

Adjusted EBITDA Guidance: Anticipated to be between $92 million and $99 million for 2026, factoring in costs associated with the Endospan acquisition.

NEXUS Launch: Expected to contribute to revenue starting January 2027, with a focus on building a dedicated sales team for this product.

4Bad News, Challenges, or Points of Concern

Free Cash Flow Decline: Significant negative free cash flow due to integration costs and transaction bonuses, raising concerns about liquidity.

R&D Investments: Increased R&D expenses impacting margins, with a noted decrease in adjusted EBITDA margin.

Market Competition: Potential competitive pressures in the aortic market, particularly with the need to educate cardiologists and surgeons on the benefits of On-X valves.

Supply Chain Issues: Ongoing supply chain challenges, particularly in international markets, with expectations for resolution by early 2027.

5Notable Q&A Insights

Guidance Maintenance: Despite a strong Q2 performance, management opted not to raise guidance due to conservatism and the need to assess ongoing market conditions.

AMDS Adoption: The PMA approval is expected to facilitate account conversions, but management cautioned against expecting an immediate surge in sales.

Sales Force Strategy: A small dedicated vascular sales team will support the NEXUS product, with existing cardiac sales teams handling AMDS and On-X, leveraging established relationships.

Integration of Endospan: Integration is progressing well, with no significant supply chain issues reported from the Endospan manufacturing facility in Israel. This summary encapsulates the key elements from the earnings call, providing a balanced view of Artivion's current performance, strategic direction, and future outlook.